Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc

References

• Havell EA. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol. 1989;143:2894–99.
   PubMed Web of Science ®Google Scholar
• Pfeffer K, Matsuyama T, Kündig TM, Wakeham A, Kishihara K, Shahinian A, Wiegmann K, Ohashi PS, Krönke M, Mak TW. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 1993;73(3):457–67. doi:10.1016/0092-8674(93)90134-C.
   PubMed Web of Science ®Google Scholar
• Rothe J, Lesslauer W, Lötscher H, Lang Y, Koebel P, Köntgen F, Althage A, Zinkernagel R, Steinmetz M, Bluethmann H. Mice lacking the tumour necrosis factor receptor 1 are resistant to IMF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993;364(6440):798–802. doi:10.1038/364798a0.
   PubMed Web of Science ®Google Scholar
• Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin JH, Patriotis C, Jenkins NA, Copeland NG, Kollias G, et al. TNF-α induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell. 2000;103(7):1071–83. doi:10.1016/S0092-8674(00)00210-5.
   PubMed Web of Science ®Google Scholar
• Segueni N, Benmerzoug S, Rose S, Gauthier A, Bourigault ML, Reverchon F, Philippeau A, Erard F, Le Bert M, Bouscayrol H, et al. Innate myeloid cell TNFR1 mediates first line defence against primary Mycobacterium tuberculosis infection. Sci Rep. 2016;6:22454. doi:10.1038/srep22454.
   PubMedGoogle Scholar
• Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, Probert L, Kollias G, McDevitt HO. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med. 1997;185(9):1573–84. doi:10.1084/jem.185.9.1573.
   PubMed Web of Science ®Google Scholar
• Aspalter RM, Wolf HM, Eibl MM. Chronic TNF-α exposure impairs TCR-signaling via TNF-RII but not TNF-RI. Cell Immunol. 2005;237(1):55–67. doi:10.1016/j.cellimm.2005.10.001.
   PubMed Web of Science ®Google Scholar
• Chen X, Baumel M, Mannel DN, Howard OMZ, Oppenheim JJ. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol. 2007;179(1):154–61. doi:10.4049/jimmunol.179.1.154.
   PubMed Web of Science ®Google Scholar
• Jacob CO, Lewis GD, McDevitt HO. MHC class II-associated variation in the production of tumor necrosis factor in mice and humans: relevance to the pathogenesis of autoimmune diseases. Immunol Res. 1991;10(2):156–68. doi:10.1007/BF02918162.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A. 1994;91(11):4854–58. doi:10.1073/pnas.91.11.4854.
   PubMed Web of Science ®Google Scholar
• Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton DJ, Hotamisligil GS, Van Obberghen E. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-α in the adipose tissue of obese mice. J Biol Chem. 2001;276(51):47944–49. doi:10.1074/jbc.M104602200.
   PubMed Web of Science ®Google Scholar
• Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF Therapy in Crohn’s Disease. Int J Mol Sci. 2018;19:8. doi:10.3390/ijms19082244.
   Web of Science ®Google Scholar
• Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2002;2(5):364–71. doi:10.1038/nri802.
   PubMed Web of Science ®Google Scholar
• Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone. 2002;30(2):340–46. doi:10.1016/S8756-3282(01)00682-2.
   PubMed Web of Science ®Google Scholar
• Müssener Å, Litton MJ, Lindroos E, Klareskog L. Cytokine production in synovial tissue of mice with collagen-induced arthritis (CIA). Clin Exp Immunol. 1997;107(3):485–93. doi:10.1046/j.1365-2249.1997.3181214.x.
   PubMed Web of Science ®Google Scholar
• Kontermann RE, Scheurich P, Pfizenmaier K. Antagonists of TNF action: clinical experience and new developments. Expert Opin Drug Discov. 2009;4(3):279–92. doi:10.1517/17460440902785167.
   PubMed Web of Science ®Google Scholar
• Sherman M, Tsynman DN, Kim A, Arora J, Pietras T, Messing S, St Hilaire L, Yoon S, Decross A, Shah A, et al. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy. J Dig Dis. 2014;15(4):174–79. doi:10.1111/1751-2980.12125.
   PubMed Web of Science ®Google Scholar
• Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease - Algorithm for practical management. Aliment Pharmacol Ther. 2016;43(1):30–51. doi:10.1111/apt.13445.
   PubMed Web of Science ®Google Scholar
• Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20(4):757–90. doi:10.1016/j.berh.2006.06.002.
   PubMed Web of Science ®Google Scholar
• Steeland S, Libert C, Vandenbroucke RE. A new venue of TNF targeting. Int J Mol Sci. 2018;19(5):1–55. doi:10.3390/ijms19051442.
   Web of Science ®Google Scholar
• Fontaine V, Mohand-Said S, Hanoteau N, Pfizenmaier K. Neurodegenerative and neuroprotective effects of Tumor Necrosis Factor (TNF) in retinal ischemia : opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci. 2002;22(7):RC216.
   Google Scholar
• Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10(1):45–65. doi:10.1038/sj.cdd.4401189.
   PubMed Web of Science ®Google Scholar
• Qu Y, Zhao G, Forward LH. Reverse signaling mediated by transmembrane tumor necrosis factor-alpha and TNF receptor 2: potential roles in an immunosuppressive tumor microenvironment. Front Immunol. 2017;8:1675. doi:10.3389/fimmu.2017.01675.
   PubMed Web of Science ®Google Scholar
• Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JPY. TNFα promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci. 2001;4(11):1116–22. doi:10.1038/nn738.
   PubMed Web of Science ®Google Scholar
• Kassiotis BG, Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of Tumor Necrosis Factor (TNF) at the p55 TNF receptor level : implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med. 2001;193(4):427–34.
   Google Scholar
• Van Hauwermeiren F, Vandenbroucke RE, Libert C. Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev. 2011;22(5–6):311–19. doi:10.1016/j.cytogfr.2011.09.004.
   PubMed Web of Science ®Google Scholar
• Williams SK, Maier O, Fischer R, Fairless R, Hochmeister S, Stojic A, Pick L, Haar D, Musiol S, Storch MK, et al. Antibody-mediated inhibition of TNFR1 attenuates disease in a mouse model of multiple sclerosis. PLoS One. 2014;9(2):e90117. doi:10.1371/journal.pone.0090117.
   PubMed Web of Science ®Google Scholar
• Shibata H, Yoshioka Y, Ohkawa A, Abe Y, Nomura T, Mukai Y, Nakagawa S, Taniai M, Ohta T, Mayumi T, et al. The therapeutic effect of TNFR1-selective antagonistic mutant TNF-α in murine hepatitis models. Cytokine. 2008;44(2):229–33. doi:10.1016/j.cyto.2008.07.003.
   PubMed Web of Science ®Google Scholar
• Shibata H, Yoshioka Y, Abe Y, Ohkawa A, Nomura T, Minowa K, Mukai Y, Nakagawa S, Taniai M, Ohta T, et al. The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF. Biomaterials. 2009;30(34):6638–47. doi:10.1016/j.biomaterials.2009.08.041.
   PubMed Web of Science ®Google Scholar
• Kitagaki M, Isoda K, Kamada H, Kobayashi T, Tsunoda S, Tsutsumi Y, Niida T, Kujiraoka T, Ishigami N, Ishihara M, et al. Novel TNF-α receptor 1 antagonist treatment attenuates arterial inflammation and intimal hyperplasia in mice. J Atheroscler Thromb. 2012;19(1):36–46. doi:10.5551/jat.9746.
   PubMed Web of Science ®Google Scholar
• Bertok S, Wilson MR, Morley PJ, de Wildt R, Bayliffe A, Takata M. Selective inhibition of intra-alveolar p55 TNF receptor attenuates ventilator-induced lung injury. Thorax. 2012;67(3):244–51. doi:10.1136/thoraxjnl-2011-200590.
   PubMed Web of Science ®Google Scholar
• Steeland S, Van Ryckeghem S, Van Imschoot G, De Rycke R, Toussaint W, Vanhoutte L, Vanhove C, De Vos F, Vandenbroucke RE, Libert C. TNFR1 inhibition with a Nanobody protects against EAE development in mice. Sci Rep. 2017;7(1):1–17. doi:10.1038/s41598-017-13984-y.
   PubMedGoogle Scholar
• Richter F, Zettlitz KA, Seifert O, Herrmann A, Scheurich P, Pfizenmaier K, Kontermann RE. Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity. MAbs. 2018;25:1–12. doi:10.1080/19420862.2018.1524664.
   Google Scholar
• Martin WL, West AP, Gan L, Bjorkman PJ. Crystal structure at 2.8 Å of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell. 2001;7(4):867–77. doi:10.1016/S1097-2765(01)00230-1.
   PubMed Web of Science ®Google Scholar
• Atwell S, Ridgway JB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol. 1997;270(1):26–35. doi:10.1006/jmbi.1997.1116.
   PubMed Web of Science ®Google Scholar
• Armour KL, Clark MR, Hadley AG, Williamson LM. Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities. Eur J Immunol. 1999;29(8):2613–24. doi:10.1002/(ISSN)1521-4141.
   PubMed Web of Science ®Google Scholar
• Zettlitz KA, Lorenz V, Landauer K, Münkel S, Herrmann A, Scheurich P, Pfizenmaier K, Kontermann RE. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs. 2010;2(6):639–47. doi:10.4161/mabs.2.6.13583.
   PubMed Web of Science ®Google Scholar
• Richter F, Liebig T, Guenzi E, Herrmann A, Scheurich P, Pfizenmaier K, Kontermann RE. Antagonistic TNF receptor one-specific antibody (ATROSAB): receptor binding and in vitro bioactivity. PLoS One. 2013;19(8):e72156. doi:10.1371/journal.pone.0072156.
   Google Scholar
• Dong Y, Fischer R, Naudé PJW, Maier O, Nyakas C, Duffey M, Van der Zee EA, Dekens D, Douwenga W, Herrmann A, et al. Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration. Proc Natl Acad Sci. 2016;113(43):12304–09. doi:10.1073/pnas.1605195113.
   PubMed Web of Science ®Google Scholar
• Ha JH, Kim JE, Kim YS. Immunoglobulin Fc heterodimer platform technology: from design to applications in therapeutic antibodies and proteins. Front Immunol. 2016;7:394. doi:10.3389/fimmu.2016.00394.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9(2):182–212. doi:10.1080/19420862.2016.1268307.
   PubMed Web of Science ®Google Scholar
• Skegro D, Stutz C, Ollier R, Svensson E, Wassmann P, Bourquin F, Monney T, Gn S, Blein S. Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodies. J Biol Chem. 2017;292(23):9745–59. doi:10.1074/jbc.M117.782433.
   PubMed Web of Science ®Google Scholar
• Feige MJ, Groscurth S, Marcinowski M, Shimizu Y, Kessler H, Hendershot LM, Buchner J. An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. Mol Cell. 2009;34(5):569–79. doi:10.1016/j.molcel.2009.04.028.
   PubMed Web of Science ®Google Scholar
• Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, Huston JS. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel. 2010;23(4):195–202. doi:10.1093/protein/gzp094.
   PubMed Web of Science ®Google Scholar
• Elkabetz Y, Argon Y, Bar-Nun S. Cysteines in CH1 underlie retention of unassembled Ig heavy chains. J Biol Chem. 2005;280(15):14402–12. doi:10.1074/jbc.M500161200.
   PubMed Web of Science ®Google Scholar
• De Nardis C, Hendriks LJA, Poirier E, Arvinte T, Gros P, Bakker ABH, De Kruif J. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1. J Biol Chem. 2017;292(35):14706–17. doi:10.1074/jbc.M117.793497.
   PubMed Web of Science ®Google Scholar
• Rathore AS, Kumar D, Kateja N. Recent developments in chromatographic purification of biopharmaceuticals. Biotechnol Lett. 2018;40(6):895–905. doi:10.1007/s10529-018-2552-1.
   PubMed Web of Science ®Google Scholar
• Li Y. A brief introduction of IgG-like bispecific antibody purification: methods for removing product-related impurities. Protein Expr Purif. 2019;155:112–19. doi:10.1016/j.pep.2018.11.011.
   PubMed Web of Science ®Google Scholar
• Martin N, Ma D, Herbet A, Boquet D, Winnik FM, Tribet C. Prevention of thermally induced aggregation of igg antibodies by noncovalent interaction with poly(acrylate) derivatives. Biomacromolecules. 2014;15(8):2952–62. doi:10.1021/bm5005756.
   PubMed Web of Science ®Google Scholar
• Brader ML, Estey T, Bai S, Alston RW, Lucas KK, Lantz S, Landsman P, Maloney KM. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies. Mol Pharm. 2015;12(4):1005–17. doi:10.1021/mp400666b.
   PubMed Web of Science ®Google Scholar
• Röthlisberger D, Honegger A, Plückthun A. Domain interactions in the Fab fragment: A comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol. 2005;347(4):773–89. doi:10.1016/j.jmb.2005.01.053.
   PubMed Web of Science ®Google Scholar
• Wozniak-Knopp G, Stadlmayr G, Perthold JW, Stadlbauer K, Gotsmy M, Becker S, Rüker F. An antibody with fab-constant domains exchanged for a pair of CH3 domains. PLoS One. 2018;13(4):e0195442. doi:10.1371/journal.pone.0195442.
   PubMed Web of Science ®Google Scholar
• Quintero-Hernández V, Juárez-González VR, Ortíz-León M, Sánchez R, Possani LD, Becerril B. The change of the scFv into the Fab format improves the stability and in vivo toxin neutralization capacity of recombinant antibodies. Mol Immunol. 2007;44(6):1307–15. doi:10.1016/j.molimm.2006.05.009.
   PubMed Web of Science ®Google Scholar
• Lord DM, Bird JJ, Honey DM, Best A, Park A, Wei RR, Qiu H. Structure-based engineering to restore high affinity binding of an isoform-selective anti-TGFβ1 antibody. MAbs. 2018;10(3):444–52. doi:10.1080/19420862.2018.1426421.
   PubMed Web of Science ®Google Scholar
• Geng SS, Feng J, Li Y, Sun Y, Gu X, Huang Y, Wang Y, Kang X, Chang H, Shen B. Binding activity difference of anti-CD20 scFv-Fc fusion protein derived from variable domain exchange. Cell Mol Immunol. 2006;3:439–43.
   PubMed Web of Science ®Google Scholar
• Wajant H. Principles of antibody-mediated TNF receptor activation. Cell Death Differ. 2015;22(11):1727–41. doi:10.1038/cdd.2015.109.
   Google Scholar
• Turaj AH, Cox KL, Penfold CA, French RR, Mockridge CI, Willoughby JE, Tutt AL, Griffiths J, Johnson PWM, Glennie MJ, et al. Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking. Sci Rep. 2018;8(1):2278. doi:10.1038/s41598-018-20656-y.
   PubMedGoogle Scholar
• Lundkvist Ryner M, Farrell RA, Fogdell-Hahn A. The case for measuring anti-drug antibodies in people with multiple sclerosis. Expert Rev Clin Immunol. 2014;10(6):697–99. doi:10.1586/1744666X.2014.914852.
   PubMed Web of Science ®Google Scholar
• Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol. 2013;32(10):1429–35. doi:10.1007/s10067-013-2336-x.
   PubMed Web of Science ®Google Scholar
• Holland MC, Wurthner JU, Morley PJ, Birchler MA, Lambert J, Albayaty M, Serone AP, Wilson R, Chen Y, Forrest RM, et al. Autoantibodies to Variable Heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1. J Clin Immunol. 2013;33(7):1192–203. doi:10.1007/s10875-013-9915-0.
   PubMed Web of Science ®Google Scholar
• Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507–32. doi:10.1023/A:1014414520282.
   PubMed Web of Science ®Google Scholar
• Hansen L, Petersen LC, Lauritzen B, Clausen JT, Grell SN, Agersø H, Sørensen BB, Hilden I, Almholt K. Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz-type protease inhibitor 2 domain of tissue factor pathway inhibitor. Thromb Res. 2014;133(3):464–71. doi:10.1016/j.thromres.2013.12.015.
   PubMed Web of Science ®Google Scholar
• Kamath AV, Yip V, Gupta P, Boswell CA, Bumbaca D, Haughney P, Castro J, Tsai SP, Pacheco G, Ross S, et al. Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice. MAbs. 2014;6(6):1631–37. doi:10.4161/mabs.36107.
   PubMed Web of Science ®Google Scholar
• Suen WE, Bergman CM, Hjelmström P, Ruddle NH. A critical role for lymphotoxin in experimental allergic encephalomyelitis. J Exp Med. 1997;186(8):1233–40. doi:10.1084/jem.186.8.1233.
   PubMed Web of Science ®Google Scholar
• O’Rourke KP, O’Donoghue G, Adams C, Mulcahy H, Molloy C, Silke C, Molloy M, Shanahan F, O’Gara F. High levels of Lymphotoxin-Beta (LT-Beta) gene expression in rheumatoid arthritis synovium: clinical and cytokine correlations. Rheumatol Int. 2008;28(10):979–86. doi:10.1007/s00296-008-0574-z.
   PubMed Web of Science ®Google Scholar
• Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P. True infliximab resistance in rheumatoid arthritis: A role for lymphotoxin alpha? Ann Rheum Dis. 2004;63(10):1344–46. doi:10.1136/ard.2003.014878.
   PubMed Web of Science ®Google Scholar
• Ji H, Cao R, Yang Y, Zhang Y, Iwamoto H, Lim S, Nakamura M, Andersson P, Wang J, Sun Y, et al. TNFR1 mediates TNF-α-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling. Nat Commun. 2014;5(1):4944. doi:10.1038/ncomms5944.
   PubMedGoogle Scholar
• Oshima H, Ishikawa T, Yoshida GJ, Naoi K, Maeda Y, Naka K, Ju X, Yamada Y, Minamoto T, Mukaida N, et al. TNF-/TNFR1 signaling promotes gastric tumorigenesis through induction of Noxo1 and Gna14 in tumor cells. Oncogene. 2014;33(29):3820–29. doi:10.1038/onc.2013.356.
   PubMed Web of Science ®Google Scholar
• Müller D, Trunk G, Sichelstiel A, Zettlitz KA, Quintanilla M, Kontermann RE. Murine endoglin-specific single-chain Fv fragments for the analysis of vascular targeting strategies in mice. J Immunol Methods. 2008;339(1):90–98. doi:10.1016/j.jim.2008.08.008.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99(3):306–14. doi:10.1016/j.cmpb.2010.01.007.
   PubMed Web of Science ®Google Scholar